

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
08 June 2023 (08.06.2023)



(10) International Publication Number
WO 2023/099669 A1

(51) International Patent Classification:
A61K 38/00 (2006.01) *C07K 7/08* (2006.01)
C07K 7/02 (2006.01)

SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/EP2022/084077

Declarations under Rule 4.17:
— of inventorship (Rule 4.17(iv))

(22) International Filing Date:
01 December 2022 (01.12.2022)

Published:
— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
21211815.2 01 December 2021 (01.12.2021) EP

(71) Applicant: **ZEALAND PHARMA A/S** [DK/DK]; Syd-
marken 11, DK-2860 Søborg (DK).

(72) Inventors: **MUNCH, Henrik Fischer**; Zealand Pharma A/
S, Sydmarken 11, DK-2860 Søborg (DK). **HOLM, Niels
Bjerre**; Zealand Pharma A/S, Sydmarken 11, DK-2860
Søborg (DK). **LETH, Rasmus**; Zealand Pharma A/S, Sy-
dmarken 11, DK-2860 Søborg (DK). **LARSEN, Bjarne
Due**; Zealand Pharma A/S, Sydmarken 11, DK-2860
Søborg (DK). **MATHIESEN, Jesper Mosolff**; Zealand
Pharma A/S, Sydmarken 11, DK-2860 Søborg (DK). **CAL-
DARU, Octav**; Zealand Pharma A/S, Sydmarken 11,
DK-2860 Søborg (DK).

(74) Agent: **MEWBURN ELLIS LLP**; Aurora Building, Coun-
terslip, Bristol BS1 6BX (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,

(54) Title: PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR

(57) Abstract: The present invention relates to compounds that are peptide inhibitors of interleukin-23 receptor (IL-23R) and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including inflammatory diseases, such as inflammatory bowel disease, such as Crohn's disease, psoriasis, and ulcerative colitis. The compounds have good physical and chemical stability in the gastrointestinal tract.

WO 2023/099669 A1